local醫學的問題,透過圖書和論文來找解法和答案更準確安心。 我們找到下列問答集和資訊懶人包

local醫學的問題,我們搜遍了碩博士論文和台灣出版的書籍,推薦寫的 Viral and Antiviral Nanomaterials: Synthesis, Properties, Characterization, and Application 和的 Africanizing Oncology: Creativity, Crisis, and Cancer in Uganda都 可以從中找到所需的評價。

另外網站割包皮名醫顧芳瑜涉詐保遭檢警搜索! 300萬交保也說明:顧芳瑜是泌尿科權威,學歷為台北醫學大學醫學士、台大醫學資訊研究所博士班,過去在台北醫學大學附設醫院擔任泌尿科主治醫師,後來在大安區開設顧芳瑜 ...

這兩本書分別來自 和所出版 。

國立陽明交通大學 分子醫學與生物工程研究所 趙啟宏所指導 王慶弘的 探討CPT1C在類基底型乳癌中調控上皮-間質轉型及腫瘤幹細胞特性所扮演的角色 (2021),提出local醫學關鍵因素是什麼,來自於脂肪酸氧化、CPT1C、類基底型乳癌、上皮-間質細胞轉型、腫瘤幹細胞特性。

而第二篇論文國立陽明交通大學 材料科學與工程學系所 柯富祥所指導 杜博瑋的 磁敏釋放控制微膠囊並應用於金屬離子螢光感測 (2021),提出因為有 微膠囊、雙乳化、釋放控制、熒光感測、磁性奈米顆粒的重點而找出了 local醫學的解答。

最後網站BMC Medicine | Home page則補充:BMC Medicine is an open access, open peer review medical journal publishing outstanding and influential research of broad interest to the biomedical and ...

接下來讓我們看這些論文和書籍都說些什麼吧:

除了local醫學,大家也想知道這些:

Viral and Antiviral Nanomaterials: Synthesis, Properties, Characterization, and Application

為了解決local醫學的問題,作者 這樣論述:

Devarajan Thangadurai, PhD, is Assistant Professor at Karnatak University, Dharwad in India and did his postdoctoral research at the University of Madeira, Portugal, University of Delhi, India, and ICAR National Research Centre for Banana, India. He is the recipient of Best Young Scientist Award wit

h Gold Medal from Acharya Nagarjuna University, India, and the VGST-SMYSR Young Scientist Award of the Government of Karnataka, India. He has interest and expertise in the fields of biotechnology and nanotechnology for sustainable future. He has authored/edited more than twenty five books with inter

national publishers in USA, Canada, Switzerland and India. He has authored/coauthored 210 publications inclusive of journal articles, book chapters, books and invited presentations. He has extensively travelled to many universities and institutes in Africa, Europe and Asia for academic works, scient

ific meetings, and international collaborations. Saher Islam, PhD, is an HEC Scholar (Higher Education Commission) of the Islamic Republic of Pakistan at the University of Veterinary and Animal Sciences, Lahore, where she received her BS, MPhil and PhD in Molecular Biology, Biotechnology and Bioinfo

rmatics. She is IRSIP Scholar at Cornell University, New York and Visiting Scholar at West Virginia State University, West Virginia in USA. She has keen research interests in genetics, molecular biology, biotechnology, and bioinformatics pertaining to animal, dairy and food science, and has ample ha

nds on experience in molecular marker analysis, whole genome sequencing and RNA sequencing. She has visited USA, UK, Singapore, Germany, Italy and Russia for academic and scientific trainings, courses, and meetings. She is the recipient of 2016 Boehringer Ingelheim Fonds Travel Grant from European M

olecular Biology Laboratory, Germany. She is an author/coauthor of 50 publications including journal articles, book chapters, books and conference presentations. Charles Oluwaseun Adetunji, PhD, is presently the Ag. Director of Intellectual Properties and Technology Transfer; Chairman Committee on R

esearch Grant and Associate Professor of Microbiology and Biotechnology at EUI. He has won several scientific awards and grants from renowned academic bodies like Council of Scientific and Industrial Research (CSIR) India, and Department of Biotechnology (DBT) India, The World Academy of Science (TW

AS) Italy, Netherlands Fellowship Programme (NPF) Netherlands, The Agency for International Development Cooperation Israel, Royal Academy of Engineering UK among many others. He has filed several scientific patents on nanobiosurfactants, nanobiopesticdes and many more. He has published over 150 scie

ntific journals and conference proceedings in international and local refereed journals. His research interest includes microbiology, biotechnology, post-harvest management, and nanotechnology. He is an editorial board member of many international journals and serves as a reviewer to many double-bli

nd peer review journals of Elsevier, Springer, Taylor and Francis, Wiley, PLOS One, Nature, American Chemistry Society, Bentham Science Publishers etc. He is a member of many scientific and professional bodies like American Society for Microbiology, Nigerian Young Academy, Biotechnology Society of N

igeria, and Nigerian Society for Microbiology. He has won international recognition and also acted as a keynote speaker delivering invited talk/position paper at various universities, research institutes and several centers of excellence which span across several continent of the globe. He has over

the last fifteen years built strong working collaborations with reputable research groups in numerous and leading Universities across the globe. He is the convener for Recent Advances in Biotechnology, which is an annual international conference where renowned microbiologists and biotechnologists co

me together to share their latest discoveries. He is also the Founder & CEO of BECTIK Biotechnology and Nanotechnology Company.

local醫學進入發燒排行的影片

前幾天指揮中心拿出一個表格比較各種疫苗之間的好壞,本意是想說AZ其實好棒棒所以大家不用擔心。但結果表格內容我看了一看之後發現結果MODERNA表現最差,每個不良反應比例都比AZ高,那你買五百萬劑還宣傳個半天幹嘛?

但我還是耐心解釋一下,這張表格做錯了,會導致民眾有錯誤的理解。

第一, 疫苗只要過了三期以後,真正致死的機率並不高,重點在於防護力好嗎?防護力低,副作用再低也沒有達到效果啊。不然喝符水好不好?沒甚麼防護力,但也沒有副作用啊?把這個副作用拿出來比較真的沒有意義啦~~~談戀愛有沒有可能被劈腿,難道你就不談戀愛嗎?

第二, 這裡列出來的表格其實是不良反應或是不良事件中的各種症狀的比例,表格做得好像有一半的人打了會有這些反應,這不是嚇死人?所謂的Adverse Event不良事件是在施用藥物產品的患者或臨床研究受試者中發生的任何不利的醫學事件,並且不一定與該治療有因果關係。因此,不良事件可以是與藥品的使用暫時相關的任何不利的和意外的跡象,症狀或疾病,無論是否與藥品有關。參加臨床試驗的患者的AE必須報告給研究發起人,必要時可以報告給當地倫理委員會。【來自維基百科】

第三, 三期實驗的狀況跟實際上臨床的狀況又不一樣啊~~~實驗歸實驗,現實世界的運作回報不良反應的機制有所不同,不是真的很嚴重到回診,其實醫師根本就不會知道,也就不會回報啊,所以要看實際接種的反應才比較準啊。

像是ADZ的這份資料是來自於WHO的三期實驗報告整理: AZD1222 vaccine against COVID-19 developed by Oxford University and Astra Zeneca: Background paper (draft),有五十二頁大家可以自己去看看,但實驗的內容其實是去年的三期實驗了,不是實際注射之後的結果。

我推薦大家看的是美國的CDC所推出來的疫苗施打第一個月報告,二月十九日出版,熱燙燙非常新。First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021。是他們實際施打疫苗一個月,一千三百萬劑之後的結果,實際上會有不良反應的比例非常低啊,大家不要自己嚇自己~~~

美國接種13794094劑,ADVERSE EVENT:總數6,994,占比0.000506,萬分之五點零六九。輕微不良反應的有6354,0.0004606,萬分之四點六零六,其中22.4%是頭痛,16.5%是疲倦,16.5%是暈眩。

嚴重不良反應的有640人。0.00004639,十萬分之四點六三九,其中回報的死亡案例有113件,其中有78件是在長照機構裡面的成員。

還給你原文夠不夠意思The most frequently reported adverse reactions were injection site tenderness (63.7%), injection site pain (54.2%), headache (52.6%), fatigue (53.1%), myalgia (44.0%), malaise (44.2%), pyrexia (includes feverishness (33.6%) and fever >38°C (7.9%)), chills (31.9%), arthralgia (26.4%) and nausea (21.9%). The incidence of subjects with at least one local or systemic solicited event after any vaccination was highest on day 1 following vaccination, decreasing to 4% and 13 %, respectively, by day 7. The most common systemic solicited AEs at day 7 were fatigue, headache and malaise.

阿宅萬事通語錄貼圖上架囉 https://reurl.cc/dV7bmD​

【加入YT會員按鈕】 https://reurl.cc/raleRb​
【訂閱YT頻道按鈕】 https://reurl.cc/Q3k0g9​
購買朱大衣服傳送門: https://shop.lucifer.tw/

探討CPT1C在類基底型乳癌中調控上皮-間質轉型及腫瘤幹細胞特性所扮演的角色

為了解決local醫學的問題,作者王慶弘 這樣論述:

代謝途徑重整是腫瘤的重要特徵之一,腫瘤細胞可藉由調控自身的代謝偏好而有利其在代謝壓力的情況下存活,並維持高速增生。有研究更進一步指出乳癌細胞傾向於透過調控脂肪酸氧化代謝的效率限制酶CPT1C來增加脂肪酸氧化的活性,進而促進細胞增生,甚至維持腫瘤幹細胞特性及產生抗藥性。因此,本研究旨在釐清類基底型乳癌是否透過調節CPT1C影響細胞脂肪酸氧化代謝的活性,進而誘發上皮-間質細胞轉型及腫瘤幹細胞特性。我們的先導結果指出,透過TCGA數據資料庫分析,CPT1C表現量在類基底型乳癌患者中高於其他乳癌類型,並在具有淋巴結轉移或遠端轉移的患者中具有較高的表現量;而在類基底型乳癌患者中,擁有較高CPT1C表現

量的族群同時存活率也較差。此外,在類基底型乳癌患者中,相較於其他CPT1同功酶(CPT1A、CPT1B), 唯有CPT1C的表現量和存活率呈現負相關。接著,正常類基底型人類乳腺上皮細胞中過度表現CPT1C會增加脂肪酸氧化代謝活性,同時也誘導上皮-間質細胞轉型、細胞遷移、侵襲,並且提升腫瘤幹細胞特性;反之,利用微小干擾RNA抑制類基底型乳癌細胞株的CPT1C表現則可降低腫瘤的發展。以上結果顯示CPT1C確實在類基底型乳癌細胞的高度上皮-間質細胞轉型及癌幹性中扮演不可或缺的角色,未來我將繼續探討調控CPT1C的分子機制及利用動物實驗進行驗證。我們的研究不僅對於新穎療法的開發有很大的幫助,也釐清現行

生酮飲食療法用於類基底型乳癌的謬誤。關鍵詞: 脂肪酸氧化、CPT1C、類基底型乳癌、上皮-間質細胞轉型、腫瘤幹細胞特性

Africanizing Oncology: Creativity, Crisis, and Cancer in Uganda

為了解決local醫學的問題,作者 這樣論述:

An innovative contemporary history that blends insights from a variety of disciplines to highlight how a storied African cancer institute has shaped lives and identities in postcolonial Uganda.Over the past decade, an increasingly visible crisis of cancer in Uganda has made local and internationa

l headlines. Based on transcontinental research and public engagement with the Uganda Cancer Institute that began in 2010, Africanizing Oncology frames the cancer hospital as a microcosm of the Ugandan state, as a space where one can trace the lived experiences of Ugandans in the twentieth century.

Ongoing ethnographic fieldwork, patient records, oral histories, private papers from US oncologists, American National Cancer Institute records, British colonial office reports, and even the architecture of the institute itself show how Ugandans understood and continue to shape ideas about national

identity, political violence, epidemics, and economic life.Africanizing Oncology describes the political, social, technological, and biomedical dimensions of how Ugandans created, sustained, and transformed this institute over the past half century. With insights from science and technology studies

and contemporary African history, Marissa Mika’s work joins a new wave of contemporary histories of the political, technological, moral, and intellectual aspirations and actions of Africans after independence. It contributes to a growing body of work on chronic disease and situates the contemporary

urgency of the mounting cancer crisis on the continent in a longer history of global cancer research and care. With its creative integration of African studies, science and technology studies, and medical anthropology, Africanizing Oncology speaks to multiple scholarly communities.

磁敏釋放控制微膠囊並應用於金屬離子螢光感測

為了解決local醫學的問題,作者杜博瑋 這樣論述:

微膠囊化技術因其在材料科學中的結構和功能性提供眾多優點而近年來受到廣泛的 關注。超分子化學是一門關注分子間非共價鍵作用力的化學學科,從中延伸出了很多 重要的概念和研究方向,例如分子螢光光探針,其螢光特性由其自身的分子結構決定, 但也容易受到環境因素的影響。在該方向上,本論文進行了詳細的研究,解釋了微膠 囊化技術與超分子化學完美的平衡組合,使其具有更好的穩定性和新穎的應用。首先 我們導入超分子化學概念通過一鍋反應合成的芘基衍生物,2­((芘­1­亞甲基) 胺) 乙醇奈 米顆粒,和通過改質的磁性奈米顆粒用作觸發釋放元素通過雙乳化溶劑蒸發法包覆在 聚己內酯聚合物基質構建的微型膠囊中。用於檢測三價陽

離子的開關感測器通過新型 的螢光響應與磁場控制釋放機制被很好地整合在整個系統中,並且在外部震盪磁場下 可以有效地發生熱能與動能的轉換。(1) 通過一鍋法成功合成了具有聚集誘導光增強特性和三價陽離子感測能力的芘基衍 生物螢光探針。我們使用重結晶技術來提高該螢光探針化合物的純度,純度評估由螢 光光譜的半高寬的值確定。通過核磁共振光譜,紫外可見光光譜,螢光光譜和熱重分 析研究了選擇性螢光探針的特性。其聚集誘導光增強特性和對於三價陽離子 (鐵/鋁/鉻) 的選擇開關特性都表現完整且性能良好。在使用這種螢光探針作為核心材料被封裝在 微膠囊中之前,本節充分地研究了其基本特性,穩定的紫外可見光及螢光光譜的結果

是在溶劑 (乙腈) 和水 (100:900; 體積比) 的比例下進行的,強力的激發光在 505 nm,也 分別顯示出其對於三價鐵/鋁/鉻金屬陽離子優異的選擇性。(2) 為了成功通過外部震盪磁場觸發微膠囊的破裂,我們將利用共沉澱法合成並通過 檸檬酸修飾以達到避免團聚現象並提高其穩定性的磁性奈米顆粒嵌入聚合物基質中。 通過由動態光散射所測量到的粒徑分佈和界面電位以及掃描電子顯微鏡觀察到的圖 像,顯示出經過修飾的磁性奈米顆粒具有良好的分散特性和相對未修飾顆粒較小的粒 徑分佈。經過修飾的磁性奈米顆粒和選擇性熒光探針分子通過雙乳化結合溶劑蒸發法 成功封裝在微膠囊中,並通過光學顯微鏡,掃描電子顯微鏡,動

態光散射儀,熱重分i析儀,X 光散射儀,和核磁共振光譜儀對其表面形貌和特征進行了全面的研究。其結 果分別表明被修飾的磁性奈米顆粒和選擇性熒光探針確實有被微膠囊封裝在內,與此 同時,本節還深入討論了殼材料的高分子量的大小,雙乳化的內部水相濃度,以及在 分離微膠囊的離心過程中的離心速率的選擇,對合成微膠囊形貌以及包封效率的影響。 我們發現當聚合物外殼採用的分子量為 80,000 的聚己內酯時,所合成的微膠囊比其他 兩種較低分子量的顯示出更好的包覆效率和更加均勻的形狀,這主要是由於採用較高 分子量的高分子時,其油相在膠囊雙乳化狀態下的固化過程可以提供更好的穩定性。 此外,將溶解在乙腈中 10 mM

的熒光探針化合物作為內部水相的濃度與其他兩種濃度 (0.1 mM, 1 mM) 相比之下,也證明該濃度下所合成的微膠囊具有更好的均勻性和包覆 效率,因為較低濃度的內部水相會導致膠囊外殼內外滲透壓的不穩定。令人驚訝的是, 我們還發現在分離微膠囊的過程中,較高的離心速率會導致微膠囊的多孔性結構的產 生,這種現象可以通過調整較低的離心速率來消除。該策略同時也為未來開發新型多 孔性結構微膠囊的設計提供了一種新的途徑。在本節中,包覆了被修飾後的磁性奈米 顆粒和選擇性螢光探針的微膠囊的釋放行為和感測滴定分別以六十攝氏度的水浴加熱, 機械破壞,和超聲波粉碎的方式模擬其在磁場破裂的條件下進行,並且分別在不同狀

態下完美地測試了其結果。(3) 最後我們巧妙地設計了通過使用外部震盪磁場的方式來觸發芘基席夫鹼螢光 探針在微膠囊中的新型磁感應釋放機制。為了控制膠囊外殼的破裂,分散在乙腈/水 (900:100; 體積比) 中新合成的磁敏微膠囊通過直接感應加熱暴露在高頻磁場下。這些微 膠囊被成功觸發破裂釋放出所包覆的選擇性螢光探針,表現出優異的聚集誘導光增強 特性,和良好的選擇性開關螢光信號用於檢測三價金屬陽離子 (鐵/鋁/鉻)。被釋放的螢 光探針的檢測極限為:2.8602 × 10−6 M (三價鋁離子), 1.5744 × 10−6 M (三價鉻離子),和 1.8988 × 10−6 M (三價鐵離子)。

該感測器平台也表現出優異的精確度和再現性,如變 異係數所示 (三價鐵離子 ≤ 2.79%, 三價鉻離子 ≤ 2.79%, 三價鋁離子 ≤ 3.76%),各金屬離 子的回收率分別為:96.5­98.7% (三價鐵離子), 96.7­99.4% (三價鉻離子), 和 94.7­98.9% (三價鋁離子)。以上結果也充分說明了本文所述的控制釋放平台對於三價金屬陽離子 (鐵/鋁/鉻) 活性和實際樣品中的偵測,在未來環境監測甚至生物醫學方面的應用有一定 的價值和潛力。